Pan and 52 national patient advocacy groups respond to the HHS blueprint to lower drug prices and reduce out-of-pocket costs

Yesterday, we joined 52 leading patient advocacy groups in submitting a letter to the U.S. Department of Health and Human Services (HHS) in response to its Request for Information regarding the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket (OOP) Costs. Our organizations represent millions of patients living with serious, life-threatening, chronic, complex and disabling conditions. The letter is a culmination of our work in June, when we came together to share perspectives, concerns and recommendations on the Blueprint.

“Patients are the top priority for all of the patient advocacy groups that have signed the letter” said PAN President and CEO Dan Klein. “We agree with HHS that we need to change the system in a way that promotes the development of affordable innovations that improve health outcomes and lower both out-of-pocket cost and the total cost of care.” 

PAN and the organizations who signed the letter agree with HHS that too many people abandon prescriptions at the pharmacy after learning their OOP expense. When patients can’t afford their prescribed therapies, they cannot remain adherent to their treatment plans, which can not only harm their health, but increase the total cost of care over time. 

Collectively, our organizations: 

  • Believe that OOP costs should not prevent people from accessing the medications they need. Until all patients have affordable access to necessary therapies, patient assistance programs must continue their critical work of providing much-needed financial support to those who require costly medications to maintain or regain their health, well-being and quality-of-life.
  • Believe there is an opportunity to work together to improve the information that is available to patients. Information provided to support patients as consumers must be meaningful, easy to understand and actionable.
  • Have concerns regarding placing too much responsibility on patients.

 To read our letter and view a list of the organizations that joined us, click here.